The aim of the study was to evaluate the efficacy of orally administered bovine lactoferrin (bLF) on Urinary Tract Infections in neonates and infants. Fifty-five patients with urinary tract infection were randomized to receive either bLF (n = 27) or an identical placebo (n = 28) for 4 weeks. The patients were assessed clinically and laboratory.
This study was a prospective randomized controlled trial at a single university medical center. Participants were neonates or infants with Urinary Tract Infection (UTI) admitted to the Neonatal and Infant Pathology Department of Children's University Hospital in the period from July 2015 to December 2017. The intervention was bovine lactoferrin at a dosage of 100 mg/day for a period of 4 weeks compared with placebo in a control group. During hospital treatment, laboratory tests were performed to evaluate the activity of inflammatory markers (C-reactive protein, procalcitonin, Interleukin-6 and Interleukin-8 levels and white blood cell count). Fifty-five patients heve been included in the study.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
55
Orally intake 1 sachet per day for 4 weeks. Lactoferrin will be dissolved in human milk or infant formula or in a 5% glucose solution.
Orally intake 1 sachet per day for 4 weeks. Maltodextrin will be dissolved in human milk or infant formula or in a 5% glucose solution.
Monitoring of parameters of inflammation.
C-reactive protein and procalcitonin levels in both groups. Comparing possible change.
Time frame: at baseline, after 5 days of treatment
Influence of lactoferrin on Interleukin-6 and Interleukin-8.
Levels of Interleukin in both groups. Comparing possible change.
Time frame: at baseline, after 5 days of treatment
Effect of lactoferrin on white blood cells.
To assess the change in the number of leukocytes, neutrophils, lymphocytes, monocytes, eosinophils and basophils.
Time frame: at baseline, after 5 days of treatment
Effect of lactoferrin on urinary inflammatory markers.
The presence of bacteria in urine and semi-quantitative measurement of white blood cells count in urine.
Time frame: at baseline, after 5 days of treatment
To evaluate the efficacy of lactoferrin in the reduction of probable recurrence of Urinary Tract Infection.
The number of recurrent Urinary Tract Infections occur due to bacterial reinfection or bacterial persistence.
Time frame: 1 month
The number of days of hospitalization.
Length of stay. Comparing possible differences in groups.
Time frame: 1 month
Evaluation of the safety of the administration of lactoferrin by monitoring possible adverse effects.
Incidence, frequency and severity of treatment emergent adverse events.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: 1 month